Maximum tumor diameter: A simple independent predictor for biochemical recurrence after radical prostatectomy

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 3, 2010, Pages 244-247

  Fukuhara, H ^a   Kume, H ^a   Suzuki, M ^a   Fujimura, T ^a   Enomoto, Y ^a   Nishimatsu, H ^a   Ishikawa, A ^a   Homma, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Biochemical recurrence; Prostatectomy; Tumor diameter

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TUMOR DIAMETER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; TUMOR VOLUME;

AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 77955708589     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.17     Document Type: Article

References (22)

1. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-565.
2. Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2005; 2: 174-182.
3. Kupelian P, Katcher J, Levin H, Zippe C, Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996; 48: 249-260.
4. Hernandez DJ, Nielsen ME, Han M, Trock BJ, Partin AW, Walsh PC et al. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 2008; 72: 172-176.
5. Carvalhal GF, Humphrey PA, Thorson P, Yan Y, Ramos CG, Catalona WJ. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer 2000; 89: 1308-1314.
6. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395-1400.
7. Mizuno R, Nakashima J, Mukai M, Ookita H, Nakagawa K, Oya M et al. Maximum tumor diameter is a simple and valuable index associated with the local extent of disease in clinically localized prostate cancer. Int J Urol 2006; 13: 951-955.
8. Mizuno R, Nakashima J, Mukai M, Okita H, Kosugi M, Kikuchi E et al. Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer. BJU Int 2009; 104: 1215-1218.
9. Nelson BA, Shappell SB, Chang SS, Wells N, Farnham SB, Smith Jr JA et al. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 2006; 97: 1169-1172.
10. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993; 149: 1478-1481.
11. Salomon L, Levrel O, Anastasiadis AG, Irani J, De La Taille A, Saint F et al. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 2003; 43: 39-44.
12. Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004; 172: 508-511.
13. Ohori M, Kattan M, Scardino PT, Wheeler TM. Radical prostatectomy for carcinoma of the prostate. Mod Pathol 2004; 17: 349-359.
14. Mouraviev V, Mayes JM, Polascik TJ. Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol 2009; 6: 205-215.
15. Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 2003; 170: 459-463.
16. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002; 60: 264-269.
17. Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV. Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostatespecific antigen failure in radical prostatectomy specimens. Validation in a cohort of 434 patients. Am J Clin Pathol 1999; 111: 641-644.
18. Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 1998; 83: 748-752.
19. Eichelberger LE, Koch MO, Daggy JK, Ulbright TM, Eble JN, Cheng L. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am J Clin Pathol 2003; 120: 386-391.
20. Eichelberger LE, Koch MO, Eble JN, Ulbright TM, Juliar BE, Cheng L. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod Pathol 2005; 18: 886-890.
21. van Oort IM, Witjes JA, Kok DE, Kiemeney LA, HulsbergenvandeKaa CA. Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer. World J Urol 2008; 26: 237-241.
22. Dvorak T, Chen MH, Renshaw AA, Loffredo M, Richie JP, D'Amico AV. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer. Urology 2005; 66: 1024-1028.